Cystic fibrosis from the gastroenterologist's perspective

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 3, 2016, Pages 175-185

  Ooi, Chee Y ^a   Durie, Peter R ^b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; PROBIOTIC AGENT; URSODEOXYCHOLIC ACID;

ACUTE APPENDICITIS; BACTERIAL OVERGROWTH; BILIARY TRACT CANCER; CANCER RISK; CAPSULE ENDOSCOPY; CHLORIDE TRANSPORT; COLON DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS ASSOCIATED LIVER DISEASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DISTAL INTESTINAL OBSTRUCTION SYNDROME; DYSBIOSIS; ENTERITIS; FIBROSING COLONOPATHY; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HUMAN; INTESTINE CANCER; INTESTINE FLORA; INTESTINE OBSTRUCTION; INTUSSUSCEPTION; LIVER CIRRHOSIS; LIVER DISEASE; MECONIUM ILEUS; NONHUMAN; PANCREAS EXOCRINE INSUFFICIENCY; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN; COMPLICATION; GASTROINTESTINAL DISEASES; PATHOLOGY; PHYSIOLOGY;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GASTROINTESTINAL DISEASES; HUMANS;

EID: 84959358838     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.226     Document Type: Review

References (122)

1. Riordan, J. R., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066 (1989
2. Walters, S.,&Mehta, A. in Cystic Fibrosis 3rd edn (eds Hodson, M., et al.) 21-45 (Edward Arnold Ltd, 2007
3. Cystic Fibrosis Foundation. Patient Registry Annual Data Report. [online], https://www.cff.org/2013-CFF-Patient-Registry-Annual-Data-Report.pdf (2013
4. Cystic Fibrosis Canada. 2013 annual report. The Canadian Cystic Fibrosis Patient Data Registry. [online], http://www.cysticfibrosis.ca/cf-care/cf-registry/(2013
5. Neglia, J. P., et al. The risk of cancer among patients with cystic fibrosis. N. Engl. J. Med. 332, 494-499 (1995
6. Maisonneuve, P., et al. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10 year study. J. Natl Cancer Inst. 95, 381-387 (2003
7. Maisonneuve, P., et al. Cancer risk in cystic fibrosis: a 20 year nationwide study from the United States. J. Natl Cancer Inst. 105, 122-129 (2013
8. Gilljam, K., et al. Clinical manifestations of cystic fibrosis among patients diagnosed in adulthood. Chest 126, 1215-1224 (2004
9. Ooi, C. Y., et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 140, 153-161 (2011
10. Ooi, C. Y., et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language? Thorax 67, 618-624 (2012
11. Ooi, C. Y., et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis? Thorax 69, 254-260 (2014
12. Ooi, C. Y.,&Durie, P. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J. Cyst. Fibros. 11, 355-362 (2012
13. Ramsey, B. W., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011
14. Wainwright, C. E., et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med. 373, 220-231 (2015
15. Beaudet, A. L.,&Tsui, L. C. A suggested nomenclature for designating mutations. Hum. Mutat. 2, 245-248 (1993
16. Terlizzi, V., et al. Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. J. Cyst. Fibros. 13, 579-584 (2014
17. Dupuis, A., et al Prevalence of meconium ileus (MIP) marks the severity of mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. http://dx.doi.org/10.1038/gim.2015.79 (2015
18. Sheppard, D. N.,&Welsh, M. J. Structure and function of the cystic fibrosis transmembrane conductance regulator chloride channel. Physiol. Rev. 79 (SUPPL 1), S23-S45 (1999
19. Quinton, P. M. Chloride impermeability in cystic fibrosis. Nature 301, 421-422 (1983
20. Stutts, M. J., et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 269, 847-850 (1995
21. Stutts, M. J. CFTR as a cAMP-regulator of Na+ channels. Science 269, 847-850 (1995
22. Gelfond, D., et al. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig. Dis. Sci. 58, 2275-2281 (2013
23. Garcia, M. A., Yang, N.,&Quinton, P. M. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J. Clin. Invest. 119, 2613-2622 (2009
24. Bombieri, C., et al. Recommendations for the classification of diseases as CFTR-related disorders. J. Cyst. Fibros. 10 (SUPPL 2), S86-S102 (2011
25. Ahmed, N., et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 52, 1159-1164 (2003
26. Kristidis, P., et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am. J. Hum. Genet. 50, 1178-1184 (1992
27. Durno, C., et al. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 123, 1857-1864 (2002
28. Augarten, A., et al. The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype. Eur. J. Gastroenterol. Hepatol. 20, 164-168 (2008
29. Gaskin, K., et al. Improved respiratory prognosis in CF patients with normal fat absorption. J. Pediatr. 100, 857-862 (1982
30. Wilschanski, M.,&Durie, P. R. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 56, 1153-1163 (2007
31. Lewindon, P. J., et al. The role of hepatic stellate cells and transforming growth factor b1 in cystic fibrosis liver disease. Am. J. Pathol. 160, 1705-1715 (2002
32. Linblad, A., Hultcrantz, R.,&Strandvik, B. Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 16, 372-381 (1992
33. Flass, T., et al. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS ONE 10, e0116967 (2015
34. Bartlett, J. R., et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 302, 1076-1083 (2009
35. Lewindon, P. J., et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 53, 193-201 (2011
36. Witters, P., et al. Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-Associated liver disease. Hepatology 53, 1064-1065 (2011
37. Lindblad, A., Glaumann, H.,&Strandvik, B. Natural history of liver disease in cystic fibrosis. Hepatology 30, 1151-1158 (1999
38. Ooi, C. Y., Nightingale, S., Durie, P.,&Freedman, S. D. Ursodeoxycholic acid in cystic fibrosis-Associated liver disease. J. Cyst. Fibros. 11, 72-73 (2012
39. Jin, W., et al. Diagnostic accuracy of the aspartate aminotransferase-To platelet ratio index for the prediction of hepatitis B related fibrosis: a leading meta-Analysis. BMC Gastroenterol. 12, 14 (2012
40. Lin, Z. H., et al. Performance of the aspartate aminotransferase-To platelet ratio index for the staging of hepatitis C related fibrosis: an updated meta-Analysis. Hepatology 53, 726-736 (2011
41. Leung, D. H., et al. Aspartate aminotransferase to platelet ratio and fibrosis 4 as biomarkers in biopsy validated pediatric cystic fibrosis liver disease. Hepatology 62, 1576-1583 (2015
42. Rath, T., et al. TIMP 1/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease. Dig. Liver Dis. 44, 780-787 (2012
43. Debray, D., Kelly, D., Houwen, R., Strandvik, B.,&Colombo, C. Best practice guidance for the diagnosis and management of cystic fibrosis-Associated liver disease. J. Cyst. Fibros. 10 (SUPPL 2), S29-S36 (2011
44. O'Brien, S. M., et al. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur. J. Gastroenterol. Hepatol. 8, 477-483 (1996
45. van de Meeberg, P. C., et al. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1 year follow up. Scand. J. Gastroenterol. 32, 369-373 (1997
46. Colombo, C., et al. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 15, 677-684 (1992
47. Lindor, K. D., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50, 808-814 (2009
48. Pozler, O., et al. Transjugular introhepatic portosystemic shunt in five children with cystic fibrosis: long-Term results. Hepatogastroenterology 50, 1111-1114 (2003
49. Lillegard, J. B., et al. A single-institution review of portosystemic shunts in children: an ongoing discussion. HPB Surg. 2010, 964597 (2010
50. Linnane, B., Oliver, M. R.,&Robinson, P. J. Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series. Arch. Dis. Child. 91, 771-773 (2006
51. Aslanidou, E., Fotoulaki, M., Tsitouridis, I.,&Nousia Arvanitakis, S. Partial splenic embolization: successful treatment of hypersplenism, secondary to biliary cirrhosis and portal hypertension in cystic fibrosis. J. Cyst. Fibros. 6, 212-214 (2007)
52. Gooding, I., et al. Variceal hemorrhage and cystic fibrosis: outcomes and implications for liver transplantation. Liver Transpl. 11, 1522-1526 (2005
53. Mendizabal, M., et al. Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data. Liver Transpl. 17, 243-250 (2011
54. Bandsma, R. H., et al. Simultaneous liver-pancreas transplantation for cystic fibrosis-related liver disease: a multicenter experience. J. Cyst. Fibros. 13, 471-477 (2014
55. Esterly, J. R.,&Oppenheimer, E. H. Observations in cystic fibrosis of the pancreas: the gallbladder. Bull. Johns Hopkins Hosp. 110, 247-268 (1962
56. Durieu, I., et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J. Hepatol. 30, 1052-1056 (1999
57. Pall, H., et al. Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J. Pediatr. 151, 255-259 (2007
58. Sheth, S., et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum. Genet. 113, 286-292 (2003
59. Kerem, E., et al. Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J. Pediatr. 114, 767-773 (1989
60. Efrati, O., et al. Meconium ileus in patients with cystic fibrosis is not a risk factor for clinical deterioration and survival: the Israeli Multicenter Study. J. Pediatr. Gastroenterol. Nutr. 50, 173-178 (2010
61. Blackman, S. M., et al. Relative contribution of genetic and non-genetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 131, 1030-1039 (2006
62. Karimi, A., et al. Issues in the management of simple and complex meconium ileus. Pediatr. Surg. Int. 27, 963-968 (2011
63. Roberts, H. E., et al. Increased frequency of cystic fibrosis among infants with jejunoileal atresia. Am. J. Med. Genet. 78, 446-449 (1998
64. Stollman, T. H., Wijnen, R. M.,&Draaisma, J. M. Investigation for cystic fibrosis in infants with jejunoileal atresia in the Netherlands: a 35 year experience with 114 cases. Eur. J. Pediatr. 166, 989-990 (2007
65. Yap, T. S., Jiwane, A., Belessis, Y.,&Ooi, C. Y. Colonic atresia presenting as neonatal bowel obstruction in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 58, e37-e38 (2014
66. Dray, X., et al. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin. Gastroenterol. Hepatol. 2, 498-503 (2004
67. Morton, J. R., et al. Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation. J. Gastrointest. Surg. 13, 1448-1453 (2009
68. Shidrawi, R., et al. Emergency colonoscopy for distal intestinal obstruction syndrome in cystic fibrosis patients. Gut 51, 285-286 (2002
69. Perez-Aguilar, F., et al. Digestive alterations in cystic fibrosis: retrospective study of a series of 46 adult patients. Gastroenterol. Hepatol. 22, 72-78 (1999
70. Smith, V. V., et al. Lymphocytic leiomyositis and myenteric ganglionitis are intrinsic features of cystic fibrosis: studies in distal intestinal obstruction syndrome and meconium ileus. J. Pediatr. Gastroenterol. Nutr. 49, 42-51 (2009
71. Houwen, R. H., et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J. Pediatr. Gastroenterol. Nutr. 50, 38-42 (2010
72. Robertson, M. D., Choe, K. A.,&Joseph, P. M. Review of the abdominal manifestations of cystic fibrosis in the adult patient. Radiographics 26, 679-690 (2006
73. Shields, M. D., et al. Appendicitis in cystic fibrosis. Arch. Dis. Child. 66, 307-310 (1991
74. Lardenoye, S. W., Puylaert, J. B., Smit, M. J.,&Holscher, H. C. Appendix in children with cystic fibrosis: US features. Radiology 232, 187-189 (2004
75. Lee, J. M., et al. Update of faecal markers of inflammation in children with cystic fibrosis. Mediators Inflamm. 2012, 948367 (2012
76. Ooi, C. Y., et al. Fecal human β-defensin 2 in children with cystic fibrosis: is there a diminished intestinal innate immune response? Dig. Dis. Sci. 60, 2946-2952 (2015
77. Hoen, A. G., et al. Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J. Pediatr. 167, 138-147 (2015
78. Schippa, S., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in fecal microbiota of cystic fibrosis patients. PLoS ONE 8, e61176 (2013
79. Bruzzese, E., et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS ONE 9, e87796 (2014
80. Duytschaever, G., et al. Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl. Environ. Microbiol. 77, 8015-8024 (2011
81. Scanlan, P. D., et al. Gut dysbiosis in cystic fibrosis. J. Cyst. Fibros. 11, 454-455 (2012
82. Madan, J. C., et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio 3, e00251-12 (2012
83. De Lisle, R. C. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G104-G111 (2007
84. Malik, B. A., Xie, Y. Y., Wine, E.,&Huynh, H. Q. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. Can. J. Gastroenterol. 25, 41-45 (2011
85. del Campo, R., et al. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study. J. Cyst. Fibros. 13, 716-722 (2014
86. Wu, T. C., McCarthy, V. P.,&Gill, V. J. Isolation rate and toxigenic potential of Clostridium difficile isolates from patients with cystic fibrosis. J. Infect. Dis. 148, 176 (1983
87. Rivlin, J., et al. Severe Clostridium difficile-Associated colitis in young patients with cystic fibrosis. J. Pediatr. 132, 177-179 (1998
88. Roberts, D. M., et al. Prevalence of giardiasis in patients with cystic fibrosis. J. Pediatr. 112, 555-559 (1988
89. Norkina, O., Burnett, T. G.,&De Lisle, R. C. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect. Immun. 72, 6040-6049 (2004
90. Smyth, R. L., et al. Intestinal inflammation in cystic fibrosis. Arch. Dis. Child. 82, 394-399 (2000
91. Werlin, S. L., et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J. Pediatr. Gastrtroenterol. Nutr. 51, 304-308 (2010
92. Bruzzese, E., Raia, V.,&Gaudiello, G. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment. Pharmacol. Ther. 20, 813-819 (2004
93. Dhaliwal, J., et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J. Pediatr. Gastrtroenterol. Nutr. 60, 521-526 (2015
94. Pang, T., et al. Elevated faecal M2 pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood? J. Gastroenterol. Hepatol. 30, 866-871 (2015
95. Lisowska, A., et al. Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis. Scand. J. Clin. Lab. Invest. 70, 322-326 (2010
96. Billings, J. L., et al. Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J. Clin. Gastroenterol. 48, e85-88 (2014
97. Gallagher, A. M.,&Gottlieb, R. A. Proliferation, not apoptosis, alters epithelial cell migration in small intestine of CFTR null mice. Am. J. Physiol. Gastroenterol. 281, G681-G687 (2001
98. Hardt, P. D., et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br. J. Cancer 91, 980-984 (2004
99. Gottlieb, R. A., Dosanjh, A. Mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in C127 cells: possible relevance to cystic fibrosis. Proc. Natl Acad. Sci. USA 93, 3587-3591 (1996
100. Mehta, A. Cystic fibrosis as a bowel cancer syndrome and the potential role of CK2. Mol. Cell. Biochem. 316, 169-175 (2008
101. Itzkowitz, S. H.,&Yio, X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G7-G17 (2004
102. Doumit, M., Krishnan, U., Jaffé, A.,&Belessis, Y. Acid and non-Acid reflux during physiotherapy in young children with cystic fibrosis. Pediatr. Pulmonol. 47, 119-124 (2012
103. Pauwels, A., et al. Gastric emptying and different types of reflux in adult patients with cystic fibrosis. Aliment. Pharmacol. Ther. 34, 799-807 (2011
104. Button, B. M., et al. Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. J. Heart Lung Transplant. 24, 1522-1529 (2005
105. Smythe, R. L., et al. Strictures of ascending colon in cystic fibrosis and high strength pancreatic enzymes. Lancet 343, 85-86 (1994
106. Borowitz, D. S., Grand, R. J.,&Durie, P. R. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J. Pediatr. 127, 681-684 (1995
107. Borowitz, D., Baker, R. D.,&Stallings, V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 35, 246-259 (2002
108. Lloyd-Still, J. D. Crohn's disease and cystic fibrosis. Dig. Dis. Sci. 39, 880-885 (1994
109. Bresso, F., et al. Potential role for the common cystic fibrosis ?F508 mutation in Crohn's disease. Inflamm. Bowel Dis. 13, 531-536 (2007
110. Bahmanyar, S., et al. Cystic fibrosis gene mutations and gastrointestinal diseases. J. Cyst. Fibros. 9, 288-291 (2010
111. Bresso, F., D'Amato, M. The cystic fibrosis F508del mutation in Crohn's disease. J. Cyst. Fibros. 10, 132 (2011
112. Rowe, S. M., et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D mediated cystic fibrosis. Am. J. Respir. Crit. Care Med. 190, 175-184 (2014
113. Harrison, M. J., Murphy, D. M.,&Plant, B. J. Ivacaftor in a G551D homozygote with cystic fibrosis. N. Engl. J. Med. 369, 1280-1282 (2013
114. Fallahi, G., et al. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk. J. Pediatr. 55, 475-478 (2013
115. Jafari, S. A., et al. Effects of probiotics on quality of life in children with cystic fibrosis; a randomized controlled trial. Iran. J. Pediatr. 23, 669-674 (2013
116. Bruzzese, E., et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin. Nutr. 26, 322-328 (2007
117. Weiss, B., et al. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr. Pulmonol. 45, 536-540 (2010
118. Hirtz, S., et al. CFTR Cl-channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 127, 1085-1095 (2004
119. Veeze, H. J., et al. Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis. Gastroenterology 101, 398-403 (1991
120. Mall, M., Hirtz, S., Gonska, T.,&Kunzelmann, K. Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J. Cyst. Fibros. 3 (SUPPL 2), 165-169 (2004
121. Dekkers, J. F., et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat. Med. 19, 939-945 (2013
122. T?n, H., et al. Improved assay for fecal calprotectin. Clin. Chim. Acta 292, 41-54 (2000